Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million ...
Hopewell-based team delivers on ProBio's promise of speed, quality, and reliability—offering a transparent, fixed-cost model and ≥85% supercoiled plasmid DNA in record time for clinical programs. At ...
HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP ...
Expansion Adds U.S. FDA and EU Annex 1 Compliant GMP Capacity with High-Throughput Manufacturing Design and Advanced Automation by Q3 2026. "As more therapies advance to late-stage development, the ...
NANJING, China--(BUSINESS WIRE)--GenScript ProBio announced today the opening of China's largest commercial GMP plasmid manufacturing facility during a ceremony at the site in Zhenjiang, Jiangsu ...
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing ...
Nucleic acid drugs are generally defined as "chemically synthesized drugs with oligonucleotides as active ingredients that exert their effects without being translated into proteins." (*2) As a new ...
TAIPEI, Sept. 29, 2025 /PRNewswire/ -- Locus Cell (TWSE: 6891), a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding (MOU) with Australia-based Cambium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback